Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial
Date of occurrence of the event: Jul 27, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Date of occurrence of the event: Jul 7, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A …
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
First Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, July 9, 2018 /PRNewswire/ — OBI Pharma, Inc., …
Announcement on the board resolution at Annual General Meeting 2018
Date of the shareholders’ meeting: Jun 27, 2018 Important resolutions (1) profit distribution/deficit compensation: the 2017 earning distribution and expense appropriation was recognized Important resolutions (2) amendments of the company …
Amendment on the announcement for 2018 Annual General Meeting (discussion notes)
Date of the board of directors resolution: May 11, 2018 Date for convening the shareholders’ meeting: June 27, 2018 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …
The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle cash-increase of common shares to issue overseas depository receipts
Date of the board of directors resolution: May 11, 2018 Source of capital increase funds: ash-increase of common shares to issue overseas depository receipts Number of shares issued: no more …
The board of directors of the company resolved to request the shareholders to authorize the board of directors to handle private placement of common shares at the Annual General Meeting
Date of the board of directors resolution: May 11, 2018 Types of the private placement: common shares Buyers of the private placement and their relationships with the company: persons stipulated …
Amendment on the announcement for 2018 Annual General Meeting
Date of the board of directors resolution: May 11, 2018 Date for convening the shareholders’ meeting: June 27, 2018 Location for convening the shareholders’ meeting: Masterlink Securities Education and Training …
Announcement of change of accountant due to internal adjustment of the accounting firm
Date of occurrence of the event: May 11, 2018 Name of the original accounting firm and name of the original CPA: PwC Taiwan, Huei-Jin Tseng; PwC Taiwan, Ming-Huei Chang Name …
Announcement based on the procedures for acquisition or disposal of assets
Name of the securities: AP Biosciences Inc. Trading date: Jan 10, 2018 to Apr 20, 2018 Trading volume, unit price, and total monetary amount of the transaction: (1) Acquired on …